JUN 23, 2017 08:23 PM PDT

Delivering A New HIV Vaccine

WRITTEN BY: Kara Marker

Creating a successful vaccine for HIV has so far been unsuccessful, but now scientists are zeroing in on two important factors for perfecting the vaccine: timing and mode of delivery.

The vaccine candidates used in the study mimic the trimeric envelope protein spikes on the surface of HIV. Rendering of HIV with envelope protein trimers clearly visible on the virus surface. Credit: La Jolla Institute for Allergy and Immunology

The potential HIV vaccine is based on neutralizing antibodies, which attach to viruses and prevent them from promoting infection. However, in the past neutralizing antibodies have been “notoriously difficult” to create in the context of targeting HIV. From the La Jolla Institute for Allergy and Immunology, researchers tested the efficacy of an optimized vaccine in non-human primates, a traditional model for studying HIV. However, the initial vaccine wasn’t successful at first.

"The animals' immune responses, although the right kind, weren't very robust and a few didn't respond at all," explained Colin Havenar-Daughton, PhD. "That caused significant concern that the immunogen wouldn't consistently trigger an effective immune response in all individuals in a human clinical trial."

They improved upon the vaccine, using subcutaneous delivery - under the skin like insulin and morphine injections. Additionally, they increased the time intervals between immunizations, ensuring a slow and steady delivery. This makes the vaccine’s effect stronger, activating the neutralizing antibodies.

"Depending on how we gave the vaccine, there was a bigger difference due to immunization route than we would have predicted," explained co-lead author Matthias Pauthner. "We can help translate what we know now into the clinic."

HIV in 2017

HIV is now relatively considered to be a “chronic, manageable disease” thanks to antiretroviral drugs that treat AIDS. Although, accessibility to these drugs isn’t guaranteed; only half of people living with HIV have access to treatment, and new people are contracting the disease every day. The new

"The vaccine candidates we worked with here are probably the most promising prototypes out there, and one will go into people in 2018," said Professor Dennis R. Burton, PhD.

The present study was published in the journal Immunity.

 

Source: La Jolla Institute for Allergy and Immunology, Healthline

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 13, 2019
Health & Medicine
NOV 13, 2019
Tick-Borne Diseases Are Rapidly Rising in the U.S.
Tick-borne diseases have significantly increased in the U.S. in the past few years. In 2016 there were 48,610 reported cases and in 2017 59,349; these...
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Aspirin Combats Tuberculosis
Tuberculosis is a global infection far from being eradicated. It currently infects more than 1,400 people per year in Australia. The deadliest form and exp...
NOV 13, 2019
Immunology
NOV 13, 2019
A Food Additive Could Make Your Cat Hypoallergenic
With 10-30% of the population reporting sensitivity to cat dander, you probably know someone with a cat allergy.  That's why scientists at Nestl&e...
NOV 13, 2019
Health & Medicine
NOV 13, 2019
Diagnosis and Treatment of Neurosarcoidosis
Sarcoidosis is a multisystem inflammatory disease characterized by the formation of non-caseating granulomas in the affected organs. The majority of p...
NOV 13, 2019
Immunology
NOV 13, 2019
New Observations of a Cancer Transcriptase
New research shows a transcriptase that helps time cell death varies in expression, and is unusually localized, in cancer cells.  The transcriptase, T...
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Effective Vaccines for Lyme Disease?
Currently, there are no effective vaccines available for the presentation of Lyme disease. The only preventive efforts present includes “guiding&rdqu...
Loading Comments...